Executive summary Women's reproductive, maternal, newborn, child, and adolescent health
(RMNCAH) is a cornerstone for the healthy development of the next generation and a …

Vaccines have been the single most significant advancement in public health, preventing
morbidity and mortality in millions of people annually. Vaccine development has traditionally …

MicroRNAs as cancer biomarkers in serum, plasma, and other body fluids are often used but
analysis of miRNA in urine is limited. We investigated the expression of selected miRNAs in …

The receptor-binding domain (RBD) of the protein S SARS-CoV-2 is considered to be one of
the appealing targets for developing a vaccine against COVID-19. The choice of an …

Vaccines protect recipients by eliciting immune responses and communities by reducing
transmission of infection. However, newer strains with markedly increased transmissibility …

Prophylactic vaccines have evolved from traditional whole-cell vaccines to safer subunit
vaccines. However, subunit vaccines still face problems, such as poor immunogenicity and …

Human papillomavirus (HPV) is a significant health burden and leading cause of virus-
induced cancers. The current commercial vaccines are genotype specific and provide little …

Human papilloma virus (HPV) is recognized as a major cause for cervical cancer among
women worldwide. Two HPV vaccines are currently available: Gardasil® and Cervarix® …

The tumor‐suppressive role of microRNA‐216a‐3p (miR‐216a‐3p) has been evidenced in
multiple tumors. Yet, the relevance of miR‐216a‐3p in cervical cancer remains undermined …

Approved in 2006, human papillomavirus (HPV) vaccines were initially targeted for girls
aged 9–14 years. Although the safety of these vaccines has been monitored through post …